Abstract

EMT represents the dominant program within advanced stages of colon cancer, where cells acquire migratory characteristics in order to invade secondary tissues and form metastasis. Where the majority of the therapeutic strategies are concentrated on the reduction of the tumor mass through different apoptotic mechanisms, the present study advocates an important role for miR-205-5p in impairment of colon cancer cells migration and restoration of the epithelial phenotype. Upon identification of a homogenous downregulated profile for miR-205-5p in colon adenocarcinoma patients, functional studies demonstrated that experimental upregulation of this sequence is able to significantly raise the levels of E-cadherin through direct inhibition of ZEB1. Moreover, the elevation in CDH1 expression was translated into functional parameters where cells lost their invasion and migratory characteristics and formed homogenous clusters through adhesion interactions. Survival analysis of colon adenocarcinoma patients revealed that low levels of miR-205-5p are associated with an unfavorable prognostic compared to those with increased expression, demonstrating the possible clinical utility of miR-205-5p replacement. Exogenous administration of miRNA mimics was not associated with significant changes in cell viability or inflammatory pathways. Therefore, the proposed strategy is aiming towards inhibition of metastasis and limitation of the tumor borders in advanced stages patients in order to prolong the survival time and to increase the efficiency of the current therapeutic strategies.

Details

Title
The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression
Author
Gulei, Diana 1 ; Lorand Magdo 2 ; Jurj, Ancuta 2 ; Raduly, Lajos 3 ; Cojocneanu-Petric, Roxana 2   VIAFID ORCID Logo  ; Moldovan, Alin 1 ; Moldovan, Cristian 1 ; Florea, Adrian 4 ; Pasca, Sergiu 2 ; Pop, Laura-Ancuta 2 ; Moisoiu, Vlad 5 ; Budisan, Liviuta 2 ; Pop-Bica, Cecilia 2 ; Ciocan, Cristina 1 ; Buiga, Rares 6 ; Mihai-Stefan Muresan 7 ; Stiufiuc, Rares 8 ; Ionescu, Calin 9 ; Berindan-Neagoe, Ioana 10 

 MEDFUTURE - Research Center for Advanced Medicine, “Iuliu-Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 Research Center for Functional Genomics, Biomedicine and Translational Medicine, ”Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 Research Center for Functional Genomics, Biomedicine and Translational Medicine, ”Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Pathophysiology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania 
 Department of Cell and Molecular Biology, Faculty of Medicine, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 Department of Pathology, “Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania 
 5th Surgical Department, Municipal Hospital, Cluj-Napoca, Romania; Surgical and Gynecological Oncology Department, “Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania; “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 MEDFUTURE - Research Center for Advanced Medicine, “Iuliu-Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Pharmaceutical Physics-Biophysics, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
 5th Surgical Department, Municipal Hospital, Cluj-Napoca, Romania; “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 
10  MEDFUTURE - Research Center for Advanced Medicine, “Iuliu-Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; Research Center for Functional Genomics, Biomedicine and Translational Medicine, ”Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Functional Genomics and Experimental Pathology, “Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania 
Pages
1-16
Publication year
2018
Publication date
Jan 2018
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1989210156
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.